{"id":240,"date":"2023-08-18T10:36:59","date_gmt":"2023-08-18T08:36:59","guid":{"rendered":"https:\/\/semmelweis.hu\/esk\/?page_id=240"},"modified":"2026-01-09T09:27:08","modified_gmt":"2026-01-09T08:27:08","slug":"leguti-virusok-elleni-vedooltasok-eredmenyessegenek-meghatarozasa-magyarorszagon-a-2021-2024-evekben","status":"publish","type":"page","link":"https:\/\/semmelweis.hu\/esk\/kutatasok\/leguti-virusok-elleni-vedooltasok-eredmenyessegenek-meghatarozasa-magyarorszagon-a-2021-2024-evekben\/","title":{"rendered":"V\u00e9d\u0151olt\u00e1sok eredm\u00e9nyess\u00e9g\u00e9nek meghat\u00e1roz\u00e1sa"},"content":{"rendered":"

\"\"<\/a><\/p>\n

Az elm\u00falt \u00e9vek pand\u00e9mi\u00e1s tapasztalatai egy\u00e9rtelm\u0171en megmutatt\u00e1k, hogy a kor\u00e1bban haszn\u00e1lt j\u00e1rv\u00e1ny\u00fcgyi monitoring rendszerek nehezen adapt\u00e1lhat\u00f3k a hirtelen fell\u00e9p\u0151, nagy j\u00e1rv\u00e1ny\u00fcgyi esem\u00e9nyek \u00e1ltal el\u0151id\u00e9zett kih\u00edv\u00e1sokhoz. Ez\u00e9rt modern, innovat\u00edv, rugalmas, pontos surveillance-rendszerek kialak\u00edt\u00e1s\u00e1ra van sz\u00fcks\u00e9g a j\u00e1rv\u00e1ny\u00fcgyi d\u00f6nt\u00e9shozatal t\u00e1mogat\u00e1s\u00e1ra.<\/a><\/p>\n

C\u00e9lunk, a l\u00e9g\u00fati k\u00f3rokoz\u00f3k<\/strong> (pl. SARS-CoV-2, influenza-, RSV \u2013 l\u00e9g\u00fati \u00f3ri\u00e1ssejtes v\u00edrus) \u00e1ltal okozott betegs\u00e9gek innovat\u00edv epidemiol\u00f3giai surveillance-rendszer\u00e9nek ki\u00e9p\u00edt\u00e9se \u00e9s m\u0171k\u00f6dtet\u00e9se, amely seg\u00edti a l\u00e9g\u00fati j\u00e1rv\u00e1nyok elleni v\u00e9dekez\u00e9st szolg\u00e1l\u00f3 inform\u00e1lt d\u00f6nt\u00e9shozatalt<\/strong>. Egy ilyen, \u00fajt\u00edpus\u00fa l\u00e9g\u00fati figyel\u0151szolg\u00e1lat alkalmas lehet arra, hogy el\u0151re jelezze a j\u00e1rv\u00e1nyok v\u00e1rhat\u00f3 lefut\u00e1s\u00e1t, a tet\u0151z\u00e9s\u00fck id\u0151pontj\u00e1t, valamint seg\u00edthet megv\u00e1laszolni olyan k\u00e9rd\u00e9seket, mint p\u00e9ld\u00e1ul: milyen terhel\u00e9s \u00e9ri az eg\u00e9szs\u00e9g\u00fcgyi ell\u00e1t\u00f3rendszert egy j\u00e1rv\u00e1ny alatt, mikor \u00e9s h\u00e1nyszor \u00e9rdemes beoltatnunk magunkat, illetve sz\u00fcks\u00e9g van-e tov\u00e1bbi int\u00e9zked\u00e9sekre (pl. kieg\u00e9sz\u00edt\u0151 maszkhaszn\u00e1latra).<\/p>\n

Surveillance-rendszer\u00fcnk adatot szolg\u00e1ltat k\u00fcl\u00f6nb\u00f6z\u0151 m\u00f3dszerrel t\u00f6rt\u00e9n\u0151 v\u00e9d\u0151olt\u00e1s eredm\u00e9nyess\u00e9gi<\/strong> (VE) vizsg\u00e1latok kivitelez\u00e9s\u00e9hez is, vagyis annak becsl\u00e9s\u00e9re, hogy az adott v\u00e9d\u0151olt\u00e1s a val\u00f3 \u00e9letben, a hazai lakoss\u00e1g k\u00f6r\u00e9ben, a vizsg\u00e1lt l\u00e9g\u00fati szezonban milyen ar\u00e1nyban el\u0151zi meg az adott fert\u0151z\u0151 betegs\u00e9get. A v\u00e9d\u0151olt\u00e1sok val\u00f3 \u00e9letben t\u00f6rt\u00e9n\u0151 eredm\u00e9nyess\u00e9g\u00e9nek folyamatos monitoroz\u00e1sa a l\u00e9g\u00fati v\u00edrusok eset\u00e9ben az\u00e9rt is kiemelked\u0151en fontos, mert ezen v\u00edrusok genetikai szerkezete folyamatosan v\u00e1ltozik, \u00edgy a megszerzett v\u00e9detts\u00e9g \u201eelavul\u201d, illetve ereje a id\u0151vel cs\u00f6kken. Ennek k\u00f6vetkezt\u00e9ben id\u0151r\u0151l id\u0151re sz\u00fcks\u00e9gess\u00e9 v\u00e1lik a v\u00e9d\u0151olt\u00e1si strat\u00e9gia folyamatos adapt\u00e1l\u00e1sa, melyhez elengedhetetlen az aktu\u00e1lis epidemiol\u00f3giai helyzet \u00e9rt\u00e9kel\u00e9se. A rendszer tov\u00e1bbi el\u0151nye, hogy a cirkul\u00e1l\u00f3 v\u00edrusvari\u00e1nsok val\u00f3s idej\u0171 monitoroz\u00e1sa r\u00e9v\u00e9n megalapozottabb aj\u00e1nl\u00e1sok tehet\u0151k az olt\u00f3anyagok \u00f6sszet\u00e9tel\u00e9re vonatkoz\u00f3an.<\/p>\n

\n

B\u0151vebben<\/h2>\n
\n\n

L\u00e9g\u00fati v\u00edrusok elleni v\u00e9d\u0151olt\u00e1sok eredm\u00e9nyess\u00e9g\u00e9nek meghat\u00e1roz\u00e1sa Magyarorsz\u00e1gon a 2021-2028. \u00e9vekben<\/span><\/h2>\n
\n

Az SE ESK az Eg\u00e9szs\u00e9gbiztons\u00e1g Nemzeti Laborat\u00f3rium (ENL) RRF-2.3.1-21-2022-00006 azonos\u00edt\u00f3sz\u00e1m\u00fa projekt keret\u00e9ben a l\u00e9g\u00fati k\u00f3rokoz\u00f3k epidemiol\u00f3giai vizsg\u00e1lat\u00e1ra 2021-ben k\u00e9t, t\u00f6bbk\u00f6zpont\u00fa kutat\u00e1si h\u00e1l\u00f3zathoz csatlakozott, melynek c\u00e9lja kezdetben, a COVID-19 elleni vakcin\u00e1k forgalomba hozatal\u00e1t k\u00f6vet\u0151en e vakcin\u00e1k v\u00e9d\u0151olt\u00e1s-eredm\u00e9nyess\u00e9g\u00e9nek monitoroz\u00e1sa volt. Vizsg\u00e1latunkat k\u00e9s\u0151bb kiterjesztett\u00fck tov\u00e1bbi l\u00e9g\u00fati k\u00f3rokoz\u00f3k, pl. influenzav\u00edrus \u00e9s RSV okozta megbeteged\u00e9sek elleni v\u00e9d\u0151olt\u00e1sok eredm\u00e9nyess\u00e9g\u00e9nek meghat\u00e1roz\u00e1s\u00e1ra is. A \u201eL\u00e9g\u00fati v\u00edrusok elleni v\u00e9d\u0151olt\u00e1sok eredm\u00e9nyess\u00e9g\u00e9nek meghat\u00e1roz\u00e1sa Magyarorsz\u00e1gon a 2021-2028. \u00e9vekben\u201d<\/strong> elnevez\u00e9s\u0171, h\u00e1ziorvosok \u00e9s k\u00f3rh\u00e1zak bevon\u00e1s\u00e1val zajl\u00f3 epidemiol\u00f3giai vizsg\u00e1lat rendelkezik az Eg\u00e9szs\u00e9g\u00fcgyi Tudom\u00e1nyos Tan\u00e1cs Tudom\u00e1nyos \u00e9s Kutat\u00e1setikai Bizotts\u00e1g\u00e1nak szakmai-etikai enged\u00e9ly\u00e9vel.<\/p>\n

A kutat\u00e1s a VEBIS (Vaccine Effectiveness, Burden and Impact Studies) h\u00e1l\u00f3zat r\u00e9szek\u00e9nt val\u00f3sul meg, sz\u00e1mos eur\u00f3pai uni\u00f3s\/eur\u00f3pai gazdas\u00e1gi t\u00e9rs\u00e9gbeli tag\u00e1llam (pl. Franciaorsz\u00e1g, Portug\u00e1lia, Spanyolorsz\u00e1g, Hollandia) r\u00e9szv\u00e9tel\u00e9vel, valamint t\u00f6bb szervezet, k\u00f6zt\u00fck az ECDC, a WHO-EURO, region\u00e1lis \u00e9s nemzeti k\u00f6zeg\u00e9szs\u00e9g\u00fcgyi int\u00e9zetek, k\u00f3rh\u00e1zak, egyetemek, valamint kis- \u00e9s k\u00f6z\u00e9pv\u00e1llalkoz\u00e1sok egy\u00fcttm\u0171k\u00f6d\u00e9s\u00e9vel. A r\u00e9sztvev\u0151 orsz\u00e1gok az adatok \u00f6sszehasonl\u00edthat\u00f3s\u00e1g\u00e1nak \u00e9rdek\u00e9ben egys\u00e9ges protokollok szerint dolgoznak, ez\u00e1ltal nemcsak orsz\u00e1gos, hanem eur\u00f3pai szinten is meghat\u00e1rozhat\u00f3 a vakcin\u00e1k eredm\u00e9nyess\u00e9ge. Ez t\u00e1mogatja az uni\u00f3s szint\u0171 j\u00e1rv\u00e1ny\u00fcgyi d\u00f6nt\u00e9shozatalt \u00e9s az olt\u00e1si strat\u00e9gi\u00e1k kidolgoz\u00e1s\u00e1t.<\/p>\n

A VEBIS projektben a l\u00e9g\u00fati v\u00edrusokr\u00f3l \u00e9s a v\u00e9d\u0151olt\u00e1sok eredm\u00e9nyess\u00e9g\u00e9r\u0151l Eur\u00f3pa-szerte k\u00e9t f\u0151 ter\u00fcleten, egym\u00e1st\u00f3l f\u00fcggetlen\u00fcl zajlik az adatgy\u0171jt\u00e9s: egyr\u00e9szt a h\u00e1ziorvosi (alapell\u00e1t\u00e1si) szinten<\/strong>, m\u00e1sr\u00e9szt a k\u00f3rh\u00e1zi ell\u00e1t\u00e1sban<\/strong>.<\/p>\n

Magyarorsz\u00e1gon a h\u00e1ziorvosok r\u00e9szv\u00e9tel\u00e9vel zajl\u00f3 vizsg\u00e1latba<\/em> a 6 h\u00f3napos \u00e9s id\u0151sebb lakoss\u00e1g k\u00f6r\u00e9b\u0151l, akut l\u00e9g\u00fati megbeteged\u00e9s (ARI)* t\u00fcnetei alapj\u00e1n meghat\u00e1rozott esetdefin\u00edci\u00f3 szerint v\u00e1logatjuk be a p\u00e1cienseket, m\u00edg a k\u00f3rh\u00e1zi vizsg\u00e1latba <\/em>a s\u00falyos akut l\u00e9g\u00fati megbeteged\u00e9ssel (SARI)** \u00e9rkez\u0151 betegek ker\u00fclnek be a megfelel\u0151 t\u00fcnetek azonos\u00edt\u00e1sa alapj\u00e1n. A l\u00e9g\u00fati fert\u0151z\u00e9s k\u00f3rokoz\u00f3j\u00e1nak azonos\u00edt\u00e1s\u00e1ra laborat\u00f3riumi m\u00f3dszert (RT-PCR) haszn\u00e1lunk, mely alapj\u00e1n kimutathat\u00f3 az influenza-, a SARS\u2011CoV\u20112, az RS v\u00edrus, vagy egy\u00e9b k\u00f3rokoz\u00f3k jelenl\u00e9te. Ezut\u00e1n \u00f6sszehasonl\u00edtjuk az \u00e1toltotts\u00e1got a laborat\u00f3riumi vizsg\u00e1lattal meger\u0151s\u00edtett esetek \u00e9s a PCR-negat\u00edv kontrollok k\u00f6z\u00f6tt. A laborat\u00f3riumi krit\u00e9riumok szerint megfelel\u0151nek min\u0151s\u00edtett l\u00e9g\u00fati mint\u00e1kat ezt k\u00f6vet\u0151en tov\u00e1bbi szekven\u00e1l\u00e1sra k\u00fcldj\u00fck, ami lehet\u0151v\u00e9 teszi a k\u00f3rokoz\u00f3k genetikai jellemz\u00e9s\u00e9t.<\/p>\n

\n

* ARI-esetdefin\u00edci\u00f3:<\/strong>\u00a0A t\u00fcnetek hirtelen kezd\u0151dnek \u00e9s az al\u00e1bbi n\u00e9gy\u00a0l\u00e9g\u00fati t\u00fcnet\u00a0k\u00f6z\u00fcl legal\u00e1bb egy fenn\u00e1ll: k\u00f6h\u00f6g\u00e9s, torokf\u00e1j\u00e1s, l\u00e9gszomj, n\u00e1tha, tov\u00e1bb\u00e1 az orvos meg\u00edt\u00e9l\u00e9se szerint a t\u00fcnetek oka fert\u0151z\u00e9s.<\/em><\/p>\n

** SARI-esetdefin\u00edci\u00f3:<\/strong>\u00a0Legal\u00e1bb 24 \u00f3r\u00e1n kereszt\u00fcl k\u00f3rh\u00e1zi \u00e1pol\u00e1sra szorul\u00f3 p\u00e1ciens, akin\u00e9l az al\u00e1bbi l\u00e9g\u00fati t\u00fcnetek k\u00f6z\u00fcl legal\u00e1bb egy jelentkezik: l\u00e1z (\u2265 38\u00b0C), k\u00f6h\u00f6g\u00e9s, l\u00e9gszomj.<\/em><\/p>\n<\/div>\n

\n

Jelen kutat\u00e1sunk el\u0151zm\u00e9nye az I-MOVE (Influenza \u2013 Monitoring Vaccine Effectiveness in Europe) h\u00e1l\u00f3zat <\/strong>kutat\u00e1sa, amelynek c\u00e9lja az influenza elleni vakcina eredm\u00e9nyess\u00e9g\u00e9nek (VE) m\u00e9r\u00e9se Eur\u00f3p\u00e1ban. A projekt 2007-ben indult, \u00e9s a 2008-9-es influenzaszezon \u00f3ta multicentrikus (t\u00f6bbk\u00f6zpont\u00fa) \u00e9s egy\u00e9b vizsg\u00e1latokat v\u00e9gez, amelyekben Magyarorsz\u00e1gr\u00f3l a jelen kutat\u00e1st (VEBIS) v\u00e9gz\u0151 szakemberek a kezdetekt\u0151l fogva r\u00e9szt vettek.<\/p>\n

A jelenleg fut\u00f3 kutat\u00e1saink els\u0151dleges c\u00e9lja<\/em> az influenza<\/em> ill. a COVID-19 elleni v\u00e9d\u0151olt\u00e1sok \u00f6sszes\u00edtett, valamint v\u00e9d\u0151olt\u00e1st\u00edpus \u00e9s -m\u00e1rka szerint vizsg\u00e1lt eredm\u00e9nyess\u00e9g\u00e9nek meghat\u00e1roz\u00e1sa epidemiol\u00f3giai m\u00f3dszerrel a h\u00e1ziorvosi ill. k\u00f3rh\u00e1zi ell\u00e1t\u00e1st ig\u00e9nyl\u0151, laborat\u00f3riumilag igazoltan influenzav\u00edrus ill. SARS-CoV-2 okozta megbeteged\u00e9s megel\u0151z\u00e9s\u00e9ben a magyar lakoss\u00e1g k\u00f6r\u00e9ben. A kutat\u00e1s h\u00e1ziorvosi \u00e1ga<\/em> a v\u00e9d\u0151olt\u00e1soknak a h\u00e1ziorvosi ell\u00e1t\u00e1sban jelentkez\u0151, k\u00f3rh\u00e1zi \u00e1pol\u00e1st nem ig\u00e9nyl\u0151 l\u00e9g\u00fati megbeteged\u00e9sek megel\u0151z\u00e9s\u00e9nek eredm\u00e9nyess\u00e9g\u00e9t, a k\u00f3rh\u00e1zi \u00e1ga<\/em> pedig a s\u00falyos, 24 \u00f3r\u00e1n\u00e1l hosszabb k\u00f3rh\u00e1zi kezel\u00e9st ig\u00e9nyl\u0151 megbeteged\u00e9sek megel\u0151z\u00e9s\u00e9nek eredm\u00e9nyess\u00e9g\u00e9t becs\u00fcli meg. A kutat\u00e1s sor\u00e1n eset-kontroll vizsg\u00e1lat<\/em>ot v\u00e9gz\u00fcnk teszt-negat\u00edv<\/em> m\u00f3dszer alkalmaz\u00e1s\u00e1val.<\/p>\n<\/div>\n

\"\"<\/a><\/p>\n

A 2025\/26. \u00e9vi l\u00e9g\u00fati szezonban az epidemiol\u00f3giai vizsg\u00e1lat h\u00e1ziorvosi \u00e1g\u00e1ban 19 v\u00e1rmegy\u00e9b\u0151l \u00e9s Budapestr\u0151l \u00f6sszesen 150 h\u00e1ziorvossal \u00e1llunk kapcsolatban, m\u00edg a k\u00f3rh\u00e1zi \u00e1gban a kutat\u00e1sba bevont betegeket 11 klinikai egys\u00e9gben k\u00f6vetj\u00fck a kezel\u00e9s\u00fck lez\u00e1r\u00e1s\u00e1ig, majd \u00e9rt\u00e9kelj\u00fck a l\u00e9g\u00fati megbeteged\u00e9s\u00fckkel kapcsolatos adatokat \u00e9s kimeneteleket. A h\u00e1ziorvosok \u00e9s a k\u00f3rh\u00e1zi szakemberek \u00e1ltal toborzott p\u00e1ciensekt\u0151l sz\u00e1rmaz\u00f3 l\u00e9g\u00fati mint\u00e1k PCR-vizsg\u00e1lat\u00e1t, valamint a mint\u00e1kb\u00f3l v\u00edrusok genetikai \u00e1llom\u00e1ny\u00e1nak kivon\u00e1s\u00e1t a Semmelweis Egyetem Laborat\u00f3riumi Medicina Int\u00e9zete v\u00e9gzi.<\/p>\n

A PCR-vizsg\u00e1lattal pozit\u00edv l\u00e9g\u00fati mint\u00e1kb\u00f3l kinyert v\u00edrusok \u00f6r\u00f6k\u00edt\u0151anyag\u00e1nak molekul\u00e1ris elemz\u00e9se alapj\u00e1n meg\u00e1llap\u00edthatjuk, hogy az adott v\u00edrus mely genetikai csoportba sorolhat\u00f3, illetve azonos\u00edthat\u00f3k az \u00faj v\u00e1ltozatok is. Ez seg\u00edt abban, hogy tov\u00e1bb pontos\u00edtsuk az ismert v\u00edrus\u00f6sszet\u00e9tel\u0171 vakcin\u00e1k eredm\u00e9nyess\u00e9g\u00e9nek \u00e9rt\u00e9kel\u00e9s\u00e9t aszerint, hogy a vakcin\u00e1t a v\u00edrus mely vari\u00e1ns\u00e1val \/alt\u00edpus\u00e1val szembeni v\u00e9delem tekintet\u00e9ben \u00e9rt\u00e9kelj\u00fck<\/em>. A v\u00edrusok mint\u00e1kb\u00f3l kivont genetikai \u00e1llom\u00e1ny\u00e1nak szekven\u00e1l\u00e1s\u00e1t a p\u00e9csi IBioScience Kft. v\u00e9gzi.<\/p>\n

A k\u00f6vetkez\u0151 \u00e9vekben\u00a0 n\u00f6velni tervezz\u00fck mind a r\u00e9sztvev\u0151 h\u00e1ziorvosok, mind a k\u00f3rh\u00e1zak sz\u00e1m\u00e1t.<\/p>\n<\/div>\n

\u00a0<\/p>\n\n<\/div>

Publik\u00e1ci\u00f3k<\/h2>\n
\n\n

Publik\u00e1ci\u00f3k<\/h2>\n
    \n
  1. Vok\u00f3 Z, T\u00fari G, Oroszi B, Belicza \u00c9, Kov\u00e1ts T, M\u00fcller V, R\u00e9thelyi J, Szij\u00e1rt\u00f3 A, Masszi T, Tak\u00e1cs I, G\u00e1l J, G\u00f6b\u00f6l Z, Szab\u00f3 A, Varga C, Becker D, Merkely B. Association between COVID-19 vaccination and progression to severe outcomes in hospitalized COVID-19 patients in Hungary during the pre-Omicron era of the COVID-19 pandemic. Virus Res. 2025 Sep 18;361:199633. doi: 10.1016\/j.virusres.2025.199633. Epub ahead of print. PMID: 40975400; PMCID: PMC12494597. https:\/\/doi.org\/10.1016\/j.virusres.2025.199633<\/a><\/li>\n
  2. Lani\u00e8ce Delaunay C, Nunes B, Monge S, de Lange M, T\u00fari G, Machado A, Latorre-Margalef N, Mlinari\u0107 I, Lazar M, Botella Rocamora P, Erdwiens A, S\u00e8ve N, Domegan L, Mart\u00ednez-Baz I, Hooiveld M, Oroszi B, Guiomar R, Sperk M, Kure\u010di\u0107 Filipovi\u0107 S, Pascu C, Linares Dopido JA, D\u00fcrrwald R, Rameix-Welti MA, McKenna A, Castilla J, van Hagen C, Knol M, Bacci S, Kaczmarek M, Kissling E; VEBIS Primary Care Vaccine Effectiveness Group. The potential bias introduced into COVID-19 vaccine effectiveness studies at primary care level due to the availability of SARS-CoV-2 tests in the general population. Int J Epidemiol. 2025 Jun 11;54(4):dyaf086. doi: 10.1093\/ije\/dyaf086. PMID: 40534212; PMCID: PMC12204317. https:\/\/dx.doi.org\/10.1093\/ije\/dyaf086<\/a><\/li>\n
  3. Kissling E, Maurel M, Pozo F, P\u00e9rez-Gimeno G, Buda S, S\u00e8ve N, Domegan L, Hooiveld M, Oroszi B, Mart\u00ednez-Baz I, Guiomar R, Latorre-Margalef N, Mlinari\u0107 I, Lazar M, Gim\u00e9nez Duran J, D\u00fcrrwald R, Enouf V, McKenna A, de Lange M, T\u00fari G, Trobajo-Sanmart\u00edn C, Gomez V, Samuelsson Hagey T, Vi\u0161ekruna Vu\u010dina V, Cherciu MC, Garc\u00eda Vazquez M, Erdwiens A, Masse S, Bennett C, Meijer A, Krist\u00f3f K, Castilla J, Rodrigues AP, Kure\u010di\u0107 Filipovi\u0107 S, Ivanciuc AE, Bacci S, Kaczmarek M; European primary care VE group. Influenza vaccine effectiveness in Europe and the birth cohort effect against influenza A(H1N1)pdm09: VEBIS primary care multicentre study, 2023\/24. Euro Surveill. 2025 Jun;30(23):2500011. doi: 10.2807\/1560-7917.ES.2025.30.23.2500011. PMID: 40511473; PMCID: PMC12164280. https:\/\/doi.org\/10.2807\/1560-7917.es.2025.30.23.2500011<\/a><\/li>\n
  4. Laniece Delaunay C, Verdasca N, Monge S, Domegan L, S\u00e8ve N, Buda S, Meijer A, Lucaccioni H, L\u00f3pez Torrijos M, McKenna A, Enouf V, D\u00fcrrwald R, In’t Velt E, de Valc\u00e1rcel Laiglesia M\u00c1, Bennett C, Masse S, Erdwiens A, Hooiveld M, Mlinari\u0107 I, T\u00fari G, Rodrigues AP, Mart\u00ednez-Baz I, Lazar M, Latorre-Margalef N, Borges V, Kaczmarek M, Bacci S, Kissling E; European primary care VE group. COVID-19 Vaccine Effectiveness Against Medically Attended Symptomatic SARS-CoV-2 Infection Among Target Groups in Europe, October 2024-January 2025, VEBIS Primary Care Network. Influenza Other Respir Viruses. 2025 May;19(5):e70120. doi: 10.1111\/irv.70120. PMID: 40395132; PMCID: PMC12093050. https:\/\/doi.org\/10.1111\/irv.70120<\/a><\/li>\n
  5. Antunes L, Rojas-Castro M, Lozano M, Mart\u00ednez-Baz I, Leroux-Roels I, Borg ML, Oroszi B, Fitzgerald M, D\u00fcrrwald R, Jancoriene L, Machado A, Petrovi\u0107 G, Lazar M, Sou\u010dkov\u00e1 L, Bacci S, Howard J, Verdasca N, Basile L, Castilla J, Ternest S, D\u017eiugyt\u0117 A, T\u00fari G, Duffy R, Hackmann C, Kuliese M, Gomez V, Makari\u0107 ZL, Marin A, Husa P, Nicolay N, Rose AMC; VEBIS SARI VE network team. Effectiveness of the XBB.1.5 COVID-19 Vaccines Against SARS-CoV-2 Hospitalisation Among Adults Aged \u2265\u200965\u2009Years During the BA.2.86\/JN.1 Predominant Period, VEBIS Hospital Study, Europe, November 2023 to May 2024. Influenza Other Respir Viruses. 2025 Mar;19(3):e70081. doi: 10.1111\/irv.70081. PMID: 40059069; PMCID: PMC11890973. https:\/\/doi.org\/10.1111\/irv.70081<\/a><\/li>\n
  6. Astier Pe\u00f1a MP, G\u00f3mez Bravo R, Gefaell Larrondo I, Ramos Del Rio L, Mira JJ, Kne\u017eevi\u0107 S, Kirkovski A, Korkmaz B\u00c7, Kosti\u0107 M, Krzto\u0144-Kr\u00f3lewiecka A, Segern\u00e4s A, Lingner H, Murauskien\u0117 L, Mortsiefer A, Nessler K, Penakacherla N, Pencheri M, Perj\u00e9s \u00c1, Petrazzuoli F, Petricek G, Sentker T, Palandri L, Petek D, Vaes B, Ilkov O, \u00dc\u00e7\u00fcnc\u00fc EK, Vinker S, Assenova R, Adler L, Bakola M, Bensemmane S, Bezd\u00ed\u010dkov\u00e1 L, Bayen S, Burgers JS, Busneag C, Tsigarovski G, Cosic Divjak A, Domeyer PJ, Fitzgerald L, Gjorgjievski D, Heleno B, Hoffmann K, Jandri\u0107-Ko\u010di\u0107 M, Neves AL, Guisado-Clavero M, Ares-Blanco S, Frese T; Eurodata Collaborative Group. Identifying essential COVID-19 indicators for primary healthcare through Delphi analysis in 31 European countries: Eurodata eDelphi study. Eur J Public Health. 2025 Aug 14:ckaf051. doi: 10.1093\/eurpub\/ckaf051. Epub ahead of print. PMID: 40810311. https:\/\/doi.org\/10.1093\/eurpub\/ckaf051<\/a><\/li>\n
  7. Maurel M, Pozo F, P\u00e9rez-Gimeno G, Buda S, S\u00e8ve N, Oroszi B, Hooiveld M, Gomez V, Domegan L, Mart\u00ednez-Baz I, Ili\u0107 M, Carnahan AS, Mihai ME, Mart\u00ednez A, Goerlitz L, Enouf V, Horv\u00e1th JK, Dijkstra F, Rodrigues AP, Bennett C, Trobajo-Sanmart\u00edn C, Mlinari\u0107 I, Latorre-Margalef N, Ivanciuc A, Lopez A, D\u00fcrrwald R, Falchi A, T\u00fari G, Meijer A, Melo A, O’Donnell J, Castilla J, Vu\u010dina VV, Hagey TS, Lazar M, Kaczmarek M, Bacci S, Kissling E; VEBIS study team. Influenza vaccine effectiveness in Europe: Results from the 2022-2023 VEBIS (Vaccine Effectiveness, Burden and Impact Studies) primary care multicentre study. Influenza Other Respir Viruses. 2024 Jan 10;18(1):e13243. doi: 10.1111\/irv.13243. PMID: 38204584; PMCID: PMC10777262. https:\/\/doi.org\/10.1111\/irv.13243<\/a><\/li>\n
  8. Antunes L, Mazagatos C, Mart\u00ednez-Baz I, Gomez V, Borg ML, Petrovi\u0107 G, Duffy R, Dufrasne FE, D\u00fcrrwald R, Lazar M, Jancoriene L, Oroszi B, Husa P, Howard J, Melo A, Pozo F, P\u00e9rez-Gimeno G, Castilla J, Machado A, D\u017eiugyt\u0117 A, Karabuva S, Fitzgerald M, Fierens S, Tolksdorf K, Popovici SO, Mickien\u0117 A, T\u00fari G, Sou\u010dkov\u00e1 L, Nicolay N, Rose AM; European Hospital Vaccine Effectiveness Group. Effectiveness of the adapted bivalent mRNA COVID-19 vaccines against hospitalisation in individuals aged \u2265\u202f60 years during the Omicron XBB lineage-predominant period: VEBIS SARI VE network, Europe, February to August, 2023. Euro Surveill. 2024 Jan;29(3):2300708. doi: 10.2807\/1560-7917.ES.2024.29.3.2300708. PMID: 38240061; PMCID: PMC10797659. https:\/\/doi.org\/10.2807\/1560-7917.es.2024.29.3.2300708<\/a><\/li>\n
  9. Maurel M, Howard J, Kissling E, Pozo F, P\u00e9rez-Gimeno G, Buda S, S\u00e8ve N, McKenna A, Meijer A, Rodrigues AP, Mart\u00ednez-Baz I, Mlinari\u0107 I, Latorre-Margalef N, T\u00fari G, Laz\u0103r M, Mazagatos C, Echeverria A, Abela S, Bourgeois M, Machado A, D\u00fcrrwald R, Petrovi\u0107 G, Oroszi B, Jancoriene L, Marin A, Husa P, Duffy R, Dijkstra F, Gallardo Garc\u00eda V, Goerlitz L, Enouf V, Bennett C, Hooiveld M, Guiomar R, Trobajo-Sanmart\u00edn C, Vi\u0161ekruna Vu\u010dina V, Samuelsson Hagey T, Lameiras Azevedo AS, Castilla J, Xuereb G, Delaere B, G\u00f3mez V, Tolksdorf K, Bacci S, Nicolay N, Kaczmarek M, Rose AM; European IVE group. Interim 2023\/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024. Euro Surveill. 2024 Feb;29(8):2400089. doi: 10.2807\/1560-7917.ES.2024.29.8.2400089. PMID: 38390651; PMCID: PMC10899813. https:\/\/doi.org\/10.2807\/1560-7917.es.2024.29.8.2400089<\/a><\/li>\n
  10. Rose AMC, Pozo F, Mart\u00ednez-Baz I, Mazagatos C, Bossuyt N, Cauchi JP, Petrovi\u0107 G, Loghin II, Vaikutyte R, Buda S, Machado A, Duffy R, Oroszi B, Howard J, Echeverria A, Andreu C, Barbezange C, D\u017eiugyt\u0117 A, Nonkovi\u0107 D, Popescu CP, Majauskaite F, Tolksdorf K, Gomez V, Domegan L, Horv\u00e1th JK, Castilla J, Garc\u00eda M, Demuyser T, Borg ML, Tabain I, Lazar M, Kubiliute I, D\u00fcrrwald R, Guiomar R, O’Donnell J, Krist\u00f3f K, Nicolay N, Bacci S, Kissling E; VEBIS SARI VE network team; Belgium SARI Surveillance Network (BelsariNet). Vaccine effectiveness against influenza hospitalisation in adults during the 2022\/2023 mixed season of influenza A(H1N1)pdm09, A(H3N2) and B circulation, Europe: VEBIS SARI VE hospital network. Influenza Other Respir Viruses. 2024 Feb;18(2):e13255. doi: 10.1111\/irv.13255. PMID: 38403302; PMCID: PMC10894713. https:\/\/doi.org\/10.1111\/irv.13255<\/a><\/li>\n
  11. Lani\u00e8ce Delaunay C, Mart\u00ednez-Baz I, S\u00e8ve N, Domegan L, Mazagatos C, Buda S, Meijer A, Kislaya I, Pascu C, Carnahan A, Oroszi B, Ili\u0107 M, Maurel M, Melo A, Sandonis Mart\u00edn V, Trobajo-Sanmart\u00edn C, Enouf V, McKenna A, P\u00e9rez-Gimeno G, Goerlitz L, de Lange M, Rodrigues AP, Lazar M, Latorre-Margalef N, T\u00fari G, Castilla J, Falchi A, Bennett C, Gallardo V, D\u00fcrrwald R, Eggink D, Guiomar R, Popescu R, Riess M, Horv\u00e1th JK, Casado I, Garc\u00eda MDC, Hooiveld M, Machado A, Bacci S, Kaczmarek M, Kissling E; European Primary Care Vaccine Effectiveness Group. COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 BA.1\/BA.2 lineages among adults and adolescents in a multicentre primary care study, Europe, December 2021 to June 2022. Euro Surveill. 2024 Mar;29(13):2300403. doi: 10.2807\/1560-7917.ES.2024.29.13.2300403. PMID: 38551095; PMCID: PMC10979526. https:\/\/doi.org\/10.2807\/1560-7917.es.2024.29.13.2300403<\/a><\/li>\n
  12. Maurel M, Mazagatos C, Goerlitz L, Oroszi B, Hooiveld M, Machado A, Domegan L, Ili\u0107 M, Popescu R, S\u00e8ve N, Mart\u00ednez-Baz I, Larrauri A, Buda S, T\u00fari G, Meijer A, Gomez V, O’Donnell J, Mlinari\u0107 I, Timnea O, Diez AO, D\u00fcrrwald R, Horv\u00e1th JK, Dijkstra F, Rodrigues AP, McKenna A, Filipovi\u0107 SK, Lazar M, Kaczmarek M, Bacci S, Kissling E; VEBIS study team. Exploring the effect of clinical case definitions on influenza vaccine effectiveness estimation at primary care level: Results from the end-of-season 2022-23 VEBIS multicentre study in Europe. Vaccine. 2024 Jun 11;42(16):3547-3554. doi: 10.1016\/j.vaccine.2024.04.060. Epub 2024 May 3. PMID: 38704257; PMCID: PMC11152456. https:\/\/doi.org\/10.1016\/j.vaccine.2024.04.060<\/a><\/li>\n
  13. Horv\u00e1th JK, T\u00fari G, Krisztalovics K, Krist\u00f3f K, Oroszi B. Vaccine Effectiveness against GP-Attended Symptomatic COVID-19 and Hybrid Immunity among Adults in Hungary during the 2022-2023 Respiratory Season Dominated by Different SARS-CoV-2 Omicron Subvariants. Vaccines (Basel). 2024 May 4;12(5):496. doi: 10.3390\/vaccines12050496. PMID: 38793747; PMCID: PMC11125656. https:\/\/doi.org\/10.3390\/vaccines12050496<\/a><\/li>\n
  14. Laniece Delaunay C, Melo A, Maurel M, Mazagatos C, Goerlitz L, O’Donnell J, Oroszi B, S\u00e8ve N, Rodrigues AP, Mart\u00ednez-Baz I, Meijer A, Mlinari\u0107 I, Latorre-Margalef N, Laz\u0103r M, P\u00e9rez-Gimeno G, D\u00fcrrwald R, Bennett C, T\u00fari G, Rameix-Welti MA, Guiomar R, Castilla J, Hooiveld M, Kure\u010di\u0107 Filipovi\u0107 S, Samuelsson Hagey T, Dijkstra F, Borges V, Ramos Mar\u00edn V, Bacci S, Kaczmarek M, Kissling E; European primary care VE group. Effectiveness of COVID-19 vaccines administered in the 2023 autumnal campaigns in Europe: Results from the VEBIS primary care test-negative design study, September 2023-January 2024. Vaccine. 2024 Jul 25;42(19):3931-3937. doi: 10.1016\/j.vaccine.2024.05.067. Epub 2024 Jun 4. Erratum in: Vaccine. 2024 Oct 3;42(23):126089. doi: 10.1016\/j.vaccine.2024.06.056. PMID: 38839521; PMCID: PMC11252666. https:\/\/doi.org\/10.1016\/j.vaccine.2024.05.067<\/a><\/li>\n
  15. Laniece Delaunay C, Mazagatos C, Mart\u00ednez-Baz I, T\u00fari G, Goerlitz L, Domegan L, Meijer A, Rodrigues AP, S\u00e8ve N, Ilic M, Latorre-Margalef N, Lazar M, Maurel M, Melo A, Andreu Ivorra B, Casado I, Horv\u00e1th JK, Buda S, Bennett C, de Lange M, Guiomar R, Enouf V, Mlinaric I, Samuelsson Hagey T, Dinu S, Rumayor M, Castilla J, Oroszi B, D\u00fcrrwald R, O’Donnell J, Hooiveld M, Gomez V, Falchi A, Kurecic Filipovic S, Dillner L, Popescu R, Bacci S, Kaczmarek M, Kissling E; VEBIS Primary Care Vaccine Effectiveness Group. COVID-19 Vaccine Effectiveness in Autumn and Winter 2022 to 2023 Among Older Europeans. JAMA Netw Open. 2024 Jul 1;7(7):e2419258. doi: 10.1001\/jamanetworkopen.2024.19258. PMID: 38949812; PMCID: PMC11217869. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.19258<\/a><\/li>\n
  16. Laniece Delaunay C, Melo A, Maurel M, Mazagatos C, Goerlitz L, O’Donnell J, Oroszi B, S\u00e8ve N, Paula Rodrigues A, Mart\u00ednez-Baz I, Meijer A, Mlinari\u0107 I, Latorre-Margalef N, Laz\u0103r M, P\u00e9rez-Gimeno G, D\u00fcrrwald R, Bennett C, T\u00fari G, Rameix-Welti MA, Guiomar R, Castilla J, Hooiveld M, Kure\u010di\u0107 Filipovi\u0107 S, Samuelsson Hagey T, Dijkstra F, Borges V, Ramos Mar\u00edn V, Bacci S, Kaczmarek M, Kissling E; European primary care VE group. Corrigendum to „Effectiveness of COVID-19 vaccines administered in the 2023 autumnal campaigns in Europe: results from the VEBIS primary care test-negative design study, September 2023-January 2024” [Vaccine 42(19) (2024)]. Vaccine. 2024 Oct 3;42(23):126089. doi: 10.1016\/j.vaccine.2024.06.056. Epub 2024 Jul 8. Erratum for: Vaccine. 2024 Jul 25;42(19):3931-3937. doi: 10.1016\/j.vaccine.2024.05.067. PMID: 38971666; PMCID: PMC11413480. https:\/\/doi.org\/10.1016\/j.vaccine.2024.06.056<\/a><\/li>\n
  17. Antunes L, Mazagatos C, Mart\u00ednez-Baz I, Naesens R, Borg ML, Petrovi\u0107 G, Fatukasi T, Jancoriene L, Machado A, Oroszi B, Husa P, Lazar M, D\u00fcrrwald R, Howard J, Melo A, P\u00e9rez-Gimeno G, Castilla J, Bernaert E, D\u017eiugyt\u0117 A, Makari\u0107 ZL, Fitzgerald M, Mickien\u0117 A, Gomez V, T\u00fari G, Sou\u010dkov\u00e1 L, Marin A, Tolksdorf K, Nicolay N, Rose AMC; European Hospital Vaccine Effectiveness Group. Early COVID-19 XBB.1.5 Vaccine Effectiveness Against Hospitalisation Among Adults Targeted for Vaccination, VEBIS Hospital Network, Europe, October 2023-January 2024. Influenza Other Respir Viruses. 2024 Aug;18(8):e13360. doi: 10.1111\/irv.13360. PMID: 39145535; PMCID: PMC11325250. https:\/\/doi.org\/10.1111\/irv.13360<\/a><\/li>\n
  18. T\u00fari G; Horv\u00e1th, Horv\u00e1th JK, Krisztalovics K, Oroszi B; Influenza vaccine effectiveness in the 2023\/2024 respiratory season in Hungary; N\u00c9PEG\u00c9SZS\u00c9G\u00dcGY 101 : 2 pp. 116-117. , 2 p. (2024) https:\/\/nepegeszsegugyi-egyesulet.hu\/sites\/default\/files\/2024-08\/e-nepeg2402.pdf<\/a><\/li>\n
  19. Allen, C Cheng ; Dominic, E Dwyer ; Mark, Holmes ; Louis, B Irving ; Graham, Simpson ; Sanjaya, Senanayake ; Tony, Korman ; N, Deborah Friedman ; Louise, Cooley ; Peter, Wark et al. Interim estimates of influenza vaccine effectiveness for the 2023\u201324 season (Northern Hemisphere) and end-of-season estimates for the 2023 season (Southern Hemisphere). The Global Influenza Vaccine Effectiveness (GIVE) Collaboration. February 2024 (2024)<\/li>\n
  20. Liliana, Antunes; Clara, Mazagatos; Iv\u00e1n, Mart\u00ednez-Baz; Reinout, Naesens ; Maria-Louise, Borg; Goranka, Petrovi\u0107; Terra, Fatukasi; Ligita, Jancoriene; Ausenda, Machado ; Beatrix, Oroszi et al. 2023\/24 COVID-19 vaccine effectiveness against hospitalisation: VEBIS European hospital multicentre study, October 2023\u2013July 2024; Konferencia absztrakt.<\/li>\n
  21. Charlotte, Lani\u00e8ce Delaunay; Aryse, Melo; Clara, Mazagatos; Luise, Goerlitz; Joan, O\u2019Donnell; Beatrix, Oroszi; No\u00e9mie, S\u00e8ve; Ana, Paula Rodrigues; Camino, Trobajo-Sanmart\u00edn; Adam, Meijer et al. Effectiveness of 2023 autumn COVID-19 vaccines in Europe: Results from the VEBIS test-negative design study at primary care level; Konferencia absztrakt.<\/li>\n
  22. Esther, Kissling; Charlotte, Lani\u00e8ce Delaunay; Clara, Mazagatos; Luise, Goerlitz; No\u00e9mie, S\u00e8ve; Lisa, Domegan; Frederika, Dijkstra; Aitziber, Echeverria; Beatrix, Oroszi; Ana, Paula Rodrigues et al. Does SARS-CoV-2 self-testing bias vaccine effectiveness estimates in test-negative studies in primary care? A simulation study to assess magnitude, direction and control of collider bias; Konferencia absztrakt.<\/li>\n
  23. Merdrignac L, Laniece Delaunay C, Verdasca N, Vega-Piris L, O’Donnell J, S\u00e8ve N, Trobajo-Sanmart\u00edn C, Buda S, Hooiveld M, Rodrigues AP, T\u00fari G, Latorre-Margalef N, Mlinari\u0107 I, Lazar M, Maurel M, Castrillejo D, Bennett C, Rameix-Welti MA, Mart\u00ednez-Baz I, D\u00fcrrwald R, Meijer A, Melo A, Oroszi B, Hagey TS, Kure\u010di\u0107 Filipovi\u0107 S, Dijkstra F, Gomez V, Bacci S, Kaczmarek M, Kissling E; VEBIS Primary Care Vaccine Effectiveness Group. Effectiveness of XBB.1.5 Vaccines Against Symptomatic SARS-CoV-2 Infection in Older Adults During the JN.1 Lineage-Predominant Period, European VEBIS Primary Care Multicentre Study, 20 November 2023-1 March 2024. Influenza Other Respir Viruses. 2024 Nov;18(11):e70009. doi: 10.1111\/irv.70009. PMID: 39523781; PMCID: PMC11551475. https:\/\/doi.org\/10.1111\/irv.70009<\/a><\/li>\n
  24. Oroszi,B.; Horv\u00e1th, J.K., T\u00fari, G., Krisztalovics, K., Krist\u00f3f, K.; COVID-19 vaccine effectiveness and hybrid immunity in the respiratory season of 2022-23 in Hungary; EUROPEAN JOURNAL OF PUBLIC HEALTH; Volume 34 : Supplement_3 pp. 390-391. , 2 p. (2024) https:\/\/doi.org\/10.1093\/eurpub\/ckae144.1004<\/a><\/li>\n
  25. Allen, C Cheng ; Dominic, E Dwyer ; Mark, Holmes ; Louis, B Irving ; Graham, Simpson ; Sanjaya, Senanayake ; Tony, Korman ; N, Deborah Friedman ; Louise, Cooley ; Peter, Wark et al.; The Global Influenza Vaccine Effectiveness (GIVE) Report. Interim estimates of influenza vaccine effectiveness for the 2022\u201323 season (Northern Hemisphere) and end-of-season estimates for the 2022 season (Southern Hemisphere) (2023)<\/li>\n
  26. Oroszi, B.; Horv\u00e1th, J.K.; T\u00fari, G.; Krisztalovics, K.; Mucs\u00e1nyin\u00e9, J.K.; COVID-19 \u00e9s szezon\u00e1lis influenza elleni v\u00e9d\u0151olt\u00e1sok eredm\u00e9nyess\u00e9ge a 2022-23-as l\u00e9g\u00fati szezonban (2023); 29. Orsz\u00e1gos V\u00e9d\u0151olt\u00e1si Tov\u00e1bbk\u00e9pz\u0151 Tanfolyam, 2023; Konferencia absztrakt.<\/li>\n
  27. Oroszi, B.; Horv\u00e1th, J.K.; T\u00fari, G.; Krisztalovics, K.; Mucs\u00e1nyin\u00e9, J.K.; A COVID-19 elleni v\u00e9d\u0151olt\u00e1si program tanuls\u00e1gai (2023); Csal\u00e1dorvos Kutat\u00f3k Orsz\u00e1gos Szervezet\u00e9nek XXI. Kongresszusa, 2023.05.19., Konferencia absztrakt.<\/li>\n
  28. Oroszi, B; Horv\u00e1th, JK; T\u00fari, G; Krisztalovics, K; Mucs\u00e1nyin\u00e9, JK; A COVID-19 elleni v\u00e9d\u0151olt\u00e1sok eredm\u00e9nyess\u00e9ge a 2022\/2023. \u00e9vi l\u00e9g\u00fati szezonban; N\u00c9PEG\u00c9SZS\u00c9G\u00dcGY 100 : 2 pp. 82-82. , 1 p. (2023)<\/li>\n
  29. Rose AM, Nicolay N, Sandonis Mart\u00edn V, Mazagatos C, Petrovi\u0107 G, Baruch J, Denayer S, Seyler L, Domegan L, Launay O, Machado A, Burgui C, Vaikutyte R, Niessen FA, Loghin II, Husa P, Aouali N, Panagiotakopoulos G, Tolksdorf K, Horv\u00e1th JK, Howard J, Pozo F, Gallardo V, Nonkovi\u0107 D, D\u017eiugyt\u0117 A, Bossuyt N, Demuyser T, Duffy R, Luong Nguyen LB, Kislaya I, Mart\u00ednez-Baz I, Gefenaite G, Knol MJ, Popescu C, Sou\u010dkov\u00e1 L, Simon M, Michelaki S, Reiche J, Ferenczi A, Delgado-Sanz C, Lovri\u0107 Makari\u0107 Z, Cauchi JP, Barbezange C, Van Nedervelde E, O’Donnell J, Durier C, Guiomar R, Castilla J, Jonikaite I, Bruijning-Verhagen PC, Lazar M, Demlov\u00e1 R, Wirtz G, Amerali M, D\u00fcrrwald R, Kunst\u00e1r MP, Kissling E, Bacci S, Valenciano M; I-MOVE-COVID-19 hospital study team; VEBIS hospital study team; Members of the I-MOVE-COVID-19 and VEBIS hospital study teams (in addition to authors above). Vaccine effectiveness against COVID-19 hospitalisation in adults (\u2265\u202f20 years) during Omicron-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021 to 2022. Euro Surveill. 2023 Nov;28(47):2300187. doi: 10.2807\/1560-7917.ES.2023.28.47.2300187. PMID: 37997665; PMCID: PMC10668256. https:\/\/doi.org\/10.2807\/1560-7917.es.2023.28.47.2300187<\/a><\/li>\n
  30. Oroszi, B.; T\u00fari, G.; Horv\u00e1th, J.K.; Covid-19 Vaccine Effectiveness in Hungary During the 2022-23 Respiratory Season Paper: P3.043 , 1 p. (2023) 9th International Conference on Infectious Disease Dynamics: P3.043, conference abstract, Konferencia absztrakt. https:\/\/papers.ssrn.com\/sol3\/papers.cfm?abstract_id=4655049<\/a><\/li>\n
  31. Oroszi, B.; Juh\u00e1sz, A.; Nagy, Cs.; Horv\u00e1th, J.K.; Mit tanulhatn\u00e1nk meg a hazai COVID-19 pand\u00e9mi\u00e1b\u00f3l a surveillance rendszer vonatkoz\u00e1s\u00e1ban?; N\u00c9PEG\u00c9SZS\u00c9G\u00dcGY 100 : 2 p. 81; (2023); https:\/\/nepegeszsegugyi-egyesulet.hu\/sites\/default\/files\/2023-08\/XVI.%20NKE%20Konferencia%20program_Miskolc_v3.pdf<\/a><\/li>\n
  32. Allen, C Cheng ; Dominic, E Dwyer ; Mark, Holmes ; Louis, B Irving ; Graham, Simpson ; Sanjaya, Senanayake ; Tony, Korman ; N, Deborah Friedman ; Louise, Cooley ; Peter, Wark et al.; Influenza vaccine effectiveness estimates for the 2022\/23 northern hemisphere season. The Global Infuenza Vaccine Effectiveness (GIVE) Collaboration. September 2023 (2023)<\/li>\n
  33. Charlotte, Lani\u00e8ce Delaunay; Clara, Mazagatos ; Gerg\u0151, T\u00fari; Frederika, Dijkstra; Ver\u00f3nica, G\u00f3mez; Luise, Goerlitz; Lisa, Domegan; No\u00e9mie, S\u00e8ve; Maja, Ilic; Inez, Martinez-Baz et al.; COVID-19 Vaccination: Assessing effectiveness; (2023); Konferencia absztrakt.<\/li>\n
  34. Charlotte, Lani\u00e8ce Delaunay; Camino, Trobajo-Sanmart\u00edn; Clara, Mazagatos; No\u00e9mie, S\u00e8ve; Beatrix, Oroszi; Frederika, Dijkstra; Ver\u00f3nica, G\u00f3mez; Luise, Goerlitz; Lisa, Domegan; Maja, Ilic et al.; COVID-19 vaccine effectiveness by number of doses received in a multicentre test-negative design study at primary care level in Europe (VEBIS); (2023); Konferencia absztrakt.<\/li>\n
  35. Marine, Maurel ; Francisco, Pozo; Luise, Goerlitz; Iv\u00e1n, Mart\u00ednez-Baz; Marit, de Lange; Neus, Latorre-Margalef; Marina, Mihai; Gloria, P\u00e9rez-Gimeno; Judit, Krisztina Horv\u00e1th; Ausenda, Machado et al. Vaccine effectiveness against influenza A(H3N2), A(H1N1)pdm09 and B: Results from the 2022\u201323 season European VEBIS primary care multicentre study; (2023); Konferencia absztrakt.<\/li>\n
  36. Fekete, Ferenc; M\u00e9szner, Zs\u00f3fia; Koml\u00f3s, Krisztina; T\u00fari, Gerg\u0151; Oroszi, Beatrix; COVID-19 a gyermekek k\u00f6r\u00e9ben \u2013 mi az, amit jelenleg tudunk, \u00e9s mi az, amit nem; N\u00c9PEG\u00c9SZS\u00c9G\u00dcGY 99 : 1 pp. 30-41. , 12 p. (2022) https:\/\/nepegeszsegugyi-egyesulet.hu\/sites\/default\/files\/2022-08\/e-nepeg2201_1.pdf<\/a><\/li>\n
  37. Oroszi, Beatrix; Ferenczi, Annam\u00e1ria ; Juh\u00e1sz, Attila; Nagy, Csilla; Ferenci, Tam\u00e1s; T\u00fari, Gerg\u0151; Horv\u00e1th, Judit Krisztina; A v\u00e9d\u0151olt\u00e1sok jelent\u0151s\u00e9ge a 18 \u00e9ven fel\u00fcli n\u00e9pess\u00e9g COVID-19-cel \u00f6sszef\u00fcgg\u0151 megbeteged\u00e9si \u00e9s hal\u00e1loz\u00e1si kock\u00e1zat\u00e1nak cs\u00f6kkent\u00e9s\u00e9ben Magyarorsz\u00e1gon, 2021. augusztus 16. \u00e9s 2022. febru\u00e1r 6. k\u00f6z\u00f6tt; N\u00c9PEG\u00c9SZS\u00c9G\u00dcGY 99: 1 pp. 132-143., 12 p. (2022); https:\/\/www.researchgate.net\/publication\/362839665_A_vedooltasok_jelentosege_a_18_even_feluli_nepesseg_COVID-19-cel_osszefuggo_megbetegedesi_es_halalozasi_kockazatanak_csokkenteseben_Magyarorszagon_2021_augusztus_16_es_2022_februar_6_kozott_The_import<\/a><\/li>\n
  38. Horv\u00e1th, Judit Krisztina; Koml\u00f3s, Krisztina; Krisztalovics, Katalin; R\u00f6st, Gergely; Oroszi, Beatrix; A COVID-19 vil\u00e1gj\u00e1rv\u00e1ny els\u0151 k\u00e9t \u00e9ve Magyarorsz\u00e1gon; N\u00c9PEG\u00c9SZS\u00c9G\u00dcGY 99: 1 pp. 6-19., 14 p. (2022) https:\/\/publicatio.bibl.u-szeged.hu\/29019\/<\/a><\/li>\n
  39. Horv\u00e1th, J. Krisztina; Ferenci, Tam\u00e1s; Ferenczi, Annam\u00e1ria; T\u00fari, Gerg\u0151; R\u00f6st, Gergely; Oroszi, Beatrix; Real-Time Monitoring of the Effectiveness of Six COVID-19 Vaccines against Laboratory-Confirmed COVID-19 in Hungary in 2021 Using the Screening Method;VACCINES (BASEL) 10 : 11 Paper: 1824 , 10 p. (2022) https:\/\/doi.org\/10.3390\/vaccines10111824<\/a><\/li>\n
  40. Oroszi, Beatrix ; Horv\u00e1th, J. Krisztina ; T\u00fari, Gerg\u0151; Krisztalovics, Katalin ; R\u00f6st, Gergely; Az epidemiol\u00f3giai surveillance \u00e9s j\u00e1rv\u00e1nymatematikai el\u0151rejelz\u00e9sek szerepe a pand\u00e9mi\u00e1s hull\u00e1mok megel\u0151z\u00e9s\u00e9ben, m\u00e9rs\u00e9kl\u00e9s\u00e9ben \u2013 hol tartunk most, \u00e9s hov\u00e1 kellene eljutni; SCIENTIA ET SECURITAS 2 : 1 pp. 38-53. , 16 p. (2021); http:\/\/real.mtak.hu\/id\/eprint\/128142<\/a><\/li>\n
  41. Merkely B, Szab\u00f3 AJ, Kosztin A, Ber\u00e9nyi E, Sebesty\u00e9n A, Lengyel C, Merkely G, Kar\u00e1dy J, V\u00e1rkonyi I, Papp C, Miseta A, Betlehem J, Buri\u00e1n K, Cs\u00f3ka I, V\u00e1s\u00e1rhelyi B, Ludwig E, Prinz G, Sink\u00f3 J, Hank\u00f3 B, Varga P, F\u00fcl\u00f6p G\u00c1, Mag K, Vok\u00f3 Z; HUNgarian COronaVirus-19 Epidemiological Research (H-UNCOVER) investigators. Novel coronavirus epidemic in the Hungarian population, a cross-sectional nationwide survey to support the exit policy in Hungary. Geroscience. 2020 Aug;42(4):1063-1074. doi: 10.1007\/s11357-020-00226-9. Epub 2020 Jul 17. PMID: 32677025; PMCID: PMC7366154.; https:\/\/doi.org\/10.1007\/s11357-020-00226-9<\/a><\/li>\n<\/ol>\n\n<\/div>

    Eredm\u00e9nyek<\/h2>\n
    \n\n

    V\u00edrusvari\u00e1nsok monitoroz\u00e1sa\u00a0<\/h2>\n

    \"\"<\/a><\/strong>A h\u00e1ziorvosi kutat\u00e1sban a 2022. m\u00e1rcius 1. \u00e9s 2025. augusztus 31. k\u00f6z\u00f6tt<\/strong>i id\u0151szakban r\u00e9sztvett 110 <\/strong>h\u00e1ziorvos \u00f6sszesen 6400<\/strong>, az\u00a0akut l\u00e9g\u00fati megbeteged\u00e9s esetdefin\u00edci\u00f3j\u00e1nak megfelel\u0151 \u00a0betegt\u0151l vett mint\u00e1t<\/strong>. A PCR-vizsg\u00e1lattal pozit\u00edv mint\u00e1kat ezt k\u00f6vet\u0151en tov\u00e1bbi szekven\u00e1l\u00e1sra k\u00fcldt\u00fck a k\u00f3rokoz\u00f3 RNS szerkezet\u00e9nek pontosabb genetikai meghat\u00e1roz\u00e1s\u00e1ra.<\/p>\n

    A k\u00f3rh\u00e1zi kutat\u00e1sban a 2022. m\u00e1rcius 1. \u00e9s 2025. augusztus 31. k\u00f6z\u00f6tt<\/strong>i id\u0151szakban r\u00e9sztvett klinikai egys\u00e9gekben \u00f6sszesen 1230<\/strong>, a\u00a0s\u00falyos akut l\u00e9g\u00fati megbeteged\u00e9s esetdefin\u00edci\u00f3j\u00e1nak megfelel\u0151 \u00a0betegt\u0151l vettek mint\u00e1t<\/strong>. A PCR-vizsg\u00e1lattal pozit\u00edv mint\u00e1kat ezt k\u00f6vet\u0151en tov\u00e1bbi szekven\u00e1l\u00e1sra k\u00fcldt\u00fck a k\u00f3rokoz\u00f3 RNS szerkezet\u00e9nek pontosabb genetikai meghat\u00e1roz\u00e1s\u00e1ra.<\/p>\n

    A h\u00e1ziorvosi \u00e9s k\u00f3rh\u00e1zi kutat\u00e1sok legfrissebb, r\u00e9szletes eredm\u00e9nyei itt olvashat\u00f3k<\/strong><\/a>.<\/p>\n

    Az Epidemiol\u00f3giai \u00e9s Surveillance K\u00f6zpont influenza-kutat\u00e1si eredm\u00e9nyei 12 m\u00e1sik eur\u00f3pai orsz\u00e1g eredm\u00e9nyeivel egy\u00fctt minden \u00e9vben hasznos\u00edt\u00e1sra ker\u00fcltek a Glob\u00e1lis Influenza V\u00e9d\u0151olt\u00e1s Eredm\u00e9nyess\u00e9g Egy\u00fcttm\u0171k\u00f6d\u00e9snek (GIVE Collaboration) az Eg\u00e9szs\u00e9g\u00fcgyi Vil\u00e1gszervezet sz\u00e1m\u00e1ra k\u00e9sz\u00edtett jelent\u00e9s\u00e9ben, amely ezen bizony\u00edt\u00e9kokra alapozta az aj\u00e1nl\u00e1s\u00e1t a k\u00f6vetkez\u0151 l\u00e9g\u00fati szezonra kifejlesztend\u0151 influenza elleni olt\u00f3anyagok \u00f6sszet\u00e9tel\u00e9r\u0151l. A h\u00e1ziorvosi \u00e9s k\u00f3rh\u00e1zi h\u00e1l\u00f3zatra alapul\u00f3 vizsg\u00e1latok eredm\u00e9nyei ezen k\u00edv\u00fcl sz\u00e1mos tudom\u00e1nyos k\u00f6zlem\u00e9nyben \u00e9s konferenci\u00e1n ker\u00fcltek ismertet\u00e9sre.<\/p>\n

    \u00a0<\/strong><\/p>\n\n<\/div>

    H\u00e1ziorvosi h\u00e1l\u00f3zat<\/h2>\n
    \n\n

    H\u00e1ziorvosi kutat\u00e1si \u00e1g<\/h2>\n

    A 2025-26. l\u00e9g\u00fati szezonban orsz\u00e1gosan 150 h\u00e1ziorvos vesz r\u00e9szt a kutat\u00e1sban, a h\u00e1l\u00f3zat b\u0151v\u00edt\u00e9se folyamatos. A h\u00e1l\u00f3zatunkba bevont h\u00e1ziorvosi praxisok t\u00e9rbeli elhelyezked\u00e9s\u00e9t az al\u00e1bbi \u00e1bra szeml\u00e9lteti.\"\"<\/p>\n

    H\u00e1ziorvosk\u00e9nt mi\u00e9rt \u00e9rdemes csatlakoznia a kutat\u00e1shoz?<\/p>\n